News Sentiment

TYRA sentiment intelligence

Tyra Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.75 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+7.0% over one week, +21.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 7.0% Price confirming higher
Trend fit Trend inactive 21.3% over four weeks
Fair value 78.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 32
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 8
TradingKey 5
Moomoo 4
PR Newswire 4
simplywall.st 4
www.marketscreener.com 3
Stock Titan 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 13
Analyst action 10
Guidance 3
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
TradingView Direct company coverage

Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA

This page from TradingView displays financial information for Tyra Biosciences, Inc. (NASDAQ:TYRA), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 11:12
Source
TradingView
Stock Traders Daily Direct company coverage

Behavioral Patterns of TYRA and Institutional Flows

This article analyzes the behavioral patterns and institutional flows for Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models. It identifies strong sentiment across all time horizons, supporting an overweight bias, and provides specific position trading, momentum breakout, and r

Tone
Positive 70/100
Event
Market update
Published
10 Jul 2026 12:10
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA

The article discusses the "Price to sales forward" metric for Tyra Biosciences, Inc. (TYRA) on the TradingView platform. It provides financial data for the company, indicating the period, value, and change percentages for this metric. The page appears to be a financial data prese

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 10:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA

This article provides financial information for Tyra Biosciences, Inc. (TYRA) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the company's enterprise value to EBIT forward data. The content appears to be a financial snapshot from a

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 04:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA

The article provides a title referencing the enterprise value to EBITDA forward for Tyra Biosciences, Inc. (NASDAQ: TYRA). It appears to be a stub or a section from a financial data platform like TradingView, offering navigation to financial data, news, and community features rel

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:42
Source
TradingView
Insider Monkey Direct company coverage

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Tyra Biosciences, Inc. (TYRA) is positioned as a promising biotech stock due to upcoming clinical milestones, particularly the anticipated complete response data from its SURF302 study in August 2026. Oppenheimer initiated coverage with an "Outperform" rating and a $50 price targ

Tone
Positive 72/100
Event
Analyst action
Published
30 Jun 2026 13:09
Source
Insider Monkey
www.marketscreener.com Direct company coverage

Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark

Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. Concurrently, the company was dropped from several other Russell benchmarks, including the Russell Small C

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 19:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark

Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being dropped from several Russell Value and Microcap indices, but added to the Russell 3000E Growth Benchmark. The com

Tone
Positive 64/100
Event
Market update
Published
29 Jun 2026 11:40
Source
www.marketscreener.com
Stock Traders Daily Direct company coverage

(TYRA) Movement Within Algorithmic Entry Frameworks

The article provides an algorithmic analysis of Tyra Biosciences Inc. (NASDAQ: TYRA), indicating strong sentiment across all time horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 10:40
Source
Stock Traders Daily
www.marketscreener.com Direct company coverage

Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index

Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been removed from the Russell Microcap Index. This follows earlier reports of its exclusion from the Russell 3000 Value Benchmark and the Russell 2500 Value Benchmark. The company, a clinical-stage biotechnology firm, focuses on develop

Tone
Negative 35/100
Event
Market update
Published
29 Jun 2026 05:48
Source
www.marketscreener.com
Insider Monkey Direct company coverage

10 Most Promising Cancer Stocks According to Wall Street Analysts

This article identifies Tyra Biosciences, Inc. (NASDAQ:TYRA) as one of the most promising cancer stocks, citing an Outperform rating and $50 price target from Oppenheimer. The firm's confidence is based on upcoming clinical milestones, particularly full response data from the SUR

Tone
Positive 74/100
Event
Analyst action
Published
28 Jun 2026 18:40
Source
Insider Monkey
Investing.com Canada Direct company coverage

Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com

This article announces that TYRA Biosciences has filed a Form 144 for June 26. A Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides only this brief detail and is published by Investing.com.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:09
Source
Investing.com Canada
Stock Titan Direct company coverage

TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026

NEXTECH VI ONCOLOGY SCSP reported four sales of TYRA (NASDAQ: TYRA) common stock in June 2026 under a Rule 144 notice, with transactions occurring on June 1, 23, 24, and 25. The sales were handled by Merrill Lynch, generating total proceeds exceeding $4 million. The filing provid

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:09
Source
Stock Titan
TradingView Direct company coverage

Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA)

This article provides an overview of Tyra Biosciences, Inc. (NASDAQ:TYRA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, earnings per share, revenue, and market capitalization. The company's upcoming

Tone
Positive 57/100
Event
Earnings
Published
26 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

TYRA Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Tyra Biosciences, Inc. (TYRA) stock, including analyst ratings, historical performance, and future earning estimates. It details the company's financial status, market capitalization, and upcoming earnings report. The piece al

Tone
Positive 66/100
Event
Analyst action
Published
26 Jun 2026 07:40
Source
TradingView
Sahm Direct company coverage

Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In?

Tyra Biosciences (TYRA) has gained attention due to recent positive Phase II results for its experimental therapy Dabogratinib, used for non-muscle invasive bladder cancer. While short-term stock momentum has cooled, long-term investors have seen significant gains. The article di

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:41
Source
Sahm
TradingKey Direct company coverage

Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Tyra Biosciences Inc (TYRA), focusing on support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, KDJ, and ATR, along with their values and directional signals. The analysis conclud

Tone
Positive 60/100
Event
Market update
Published
23 Jun 2026 03:40
Source
TradingKey
富途牛牛 Direct company coverage

Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50

Oppenheimer has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its price target at $50. This continued endorsement by the firm suggests a positive outlook on the company's future performance and valuation. Investors may use this information as part o

Tone
Positive 75/100
Event
Analyst action
Published
19 Jun 2026 19:10
Source
富途牛牛
TradingKey Direct company coverage

Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing its major shareholders by proportion as well as a breakdown of shareholder types, including venture capital, hedge funds, and individual investors. It also provides institutional shareholding d

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Tyra Biosciences Inc (TYRA) regarding its dividend history and stock splits. It states that no dividends have been distributed over the past five years and no stock split data is available. The article serves as a record of financial events fo

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 04:39
Source
TradingKey
TradingKey Direct company coverage

Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Tyra Biosciences Inc (TYRA), detailing analyst ratings, price targets, and EPS estimates. Based on 15 analysts, the stock has a "Buy" consensus rating with a target price of USD 31.00, suggesting an 81.75% upside. The company's previ

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 15:09
Source
TradingKey
GuruFocus Direct company coverage

TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy

Jones Trading initiated coverage on Tyra Biosciences (TYRA) with a Buy rating and a $56.00 price target. This positive outlook is supported by endorsements from other analysts, although the company's GF Score™ of 30 and recent insider selling activity suggest potential risks that

Tone
Positive 67/100
Event
Analyst action
Published
17 Jun 2026 15:09
Source
GuruFocus
TradingKey Direct company coverage

Tyra Biosciences Inc (TYRA) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in Tyra Biosciences Inc (TYRA). It lists the institutional shareholders and their shareholdings, highlighting changes in their positions. The primary focus is on the "Institutional Shareholding" and "Sh

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 14:09
Source
TradingKey
Moomoo Direct company coverage

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

BofA Securities reiterated its Underperform rating and $3 price target for Tyra Biosciences, noting weak investor sentiment due to macro pressures and renewed concerns about the SURF-302 program's competitive landscape. The analyst highlights that despite the unmet need in HR+ /H

Tone
Negative 29/100
Event
Analyst action
Published
10 Jun 2026 22:39
Source
Moomoo
Barchart Direct company coverage

Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity

The Urothelial Carcinoma market is projected for significant expansion by 2036, driven by an increasing incidence of bladder cancer, advancements in immunotherapies and targeted therapies, and a strong pipeline of novel drugs. Key players like Bristol-Myers Squibb, Astellas Pharm

Tone
Positive 66/100
Event
Market update
Published
10 Jun 2026 19:10
Source
Barchart